TREATMENT
Tucatinib plus trastuzumab shows 38% response in HER2-amplified cancersA phase II trial of 32 patients with HER2 alterations found a 38% response rate in HER2-amplified tumors (including one KRAS co-mutated colon cancer) and 6% in HER2-mutated cancers, with median progression-free survival of 7.4 and 4.0 months, respectively. (NPJ Precis Oncol)